Coherus Biosciences (CHRS) Is One of the Best Penny Stocks, Here is Why

Coherus Oncology Inc. (NASDAQ:CHRS) is one of the 10 best penny stocks that could triple your money. On March 10, Coherus ...
Zacks Investment Research on MSN

Coherus Oncology (CHRS) upgraded to buy: Here's what you should know

Coherus Oncology (CHRS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Nasdaq

Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates

Coherus Oncology (CHRS) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.01 per share a year ago. These figures ...
来自MSN

Coherus Biosciences Divests UDENYCA Business

An update from Coherus Biosciences ( (CHRS)) is now available. On April 11, 2025, Coherus Biosciences sold its UDENYCA business, marking a significant divestiture of its biosimilar businesses, which ...